Stockreport

Soligenix (SNGX) Highlights HyBryte Clinical Data in Peer-Reviewed Journal Publication [Yahoo! Finance]

Soligenix, Inc.  (SNGX) 
NASDAQ:AMEX Investor Relations: soligenix.com/investors
PDF company focused on rare diseases, announced that a comprehensive summary of clinical trials evaluating HyBryte(TM) (synthetic hypericin) for cutaneous T-cell lymphoma ha [Read more]